MS Drug Going Generic Without Making Waves
Before reading this Article please remember the old adage- “No need to fix what is not broken” – (no need…
Researchers Suggest Short Transition Period Between Natalizumab and Fingolimod Therapies to Control RRMS Disease Activity
An international team led by researchers at the University Hospital Basel in Switzerland revealed that a short period of 8 to…
Stuart Schlossman
Canadians with Multiple Sclerosis One Step Closer to Accessing LEMTRADA®
Common Drug Review recommends funding the only MS treatment given once a year for two years MISSISSAUGA, ON, June 22, 2015 /CNW/…
Stuart Schlossman
PROGRESSIVE MS – a Sharper Focus
Progressive multiple sclerosis is a form of multiple sclerosis that is characterized as having nerve degeneration (the breakdown…
Stuart Schlossman
Women’s Health Issues with Multiple Sclerosis – from Altamonte Springs, Florida
Program Date: June 3, 2015 Dear MS Friends, We have had several locations with this topic and we have had…
Stuart Schlossman
Sandoz announces US launch of Glatopa(TM), the first generic competitor to Copaxone® 20mg
June 18, 2015 – Novartis International AG / Sandoz announces US launch of Glatopa(TM), the first generic competitor to Copaxone(R)…
Stuart Schlossman
MediciNova Announces Update On Phase 2b Trial of MN-166 (Ibudilast) Involving 255 Progressive MS Patients
MediciNova, Inc., a biopharmaceutical company focused on acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet…
Stuart Schlossman
Review Suggests PEG-IFN Therapy for Relapsing-Remitting Multiple Sclerosis Significantly Reduces Relapse Rates
A study recently published in the journal PLoS One compared the use of a specific treatment based on interferon beta-1a with other…
Stuart Schlossman
MSology – Multiple Sclerosis Booklets Essential to Understanding New Medications
New MS Essentials series from MSology provides critical info to people affected by multiple sclerosis (MS) MONTREAL, QUEBEC–(Marketwired – May…
Stuart Schlossman
Rebif® (interferon beta-1a) Data at CMSC Annual Meeting Highlights Clinical and MRI Predictors for Long Term Outcomes
ROCKLAND, Mass., May 21, 2015 /PRNewswire/ — EMD Serono, Inc., the U.S. biopharmaceuticals business of Merck KGaA, Darmstadt, Germany, announced today…
Stuart Schlossman
